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Neurite outgrowthAxotomised retinal ganglion cells (RGCs) die rapidly by apoptosis and fail to regenerate because of the limited
availability of neurotrophic factors and a lack of axogenic stimuli. However, we have recently showed that
pigment epithelium-derived factor (PEDF) promotes RGC survival and axon regeneration after optic nerve
crush injury. PEDF has multiple fragments of the native peptide that are neuroprotective, anti-angiogenic and
anti-inﬂammatory. Here we investigated the neuroprotective and axogenic properties of a fragment of PEDF,
PEDF-34, in retinal neurons in vitro and when delivered by intravitreal injection and eye drops in vivo. We
found that PEDF-34 was 43%more neuroprotective and 52%more neuritogenic than PEDF-44 in vitro. Moreover,
in vivo, intravitreal delivery of 1.88 nM PEDF-34 was 71% RGC neuroprotective at 21 days after optic nerve crush
compared to intact controls, whilst daily eye drops containing 1.88 nM PEDF-34 promoted 87% RGC survival.
After topical eye drop delivery, PEDF-34was detected in the vitreous bodywithin 30min and attained physiolog-
ically relevant concentrations in the retina by 4 h peaking at 1.4 ± 0.05 nM by 14 days. In eye drop- compared to
intravitreal-treated PEDF-34 animals, 55% more RGC axons regenerated 250 μm beyond the optic nerve lesion.
We conclude that daily topical eye drop application of PEDF-34 is superior to weekly intravitreal injections in
promoting RGC survival and axon regeneration through both direct effects on retinal neurons and indirect effects
on other retinal cells.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The 50 kDa neurotrophic factor pigment epithelium-derived factor
(PEDF) is a member of the serpin superfamily, ﬁrst isolated from foetal
retinal pigment epithelial cells but expression in normal choroid, ciliary
body, corneal epithelium, retinal ganglion cells (RGCs) and photorecep-
tors has since been reported (Barnstable and Tombran-Tink, 2004;
Karakousis et al., 2001; Lange et al., 2008; Ogata et al., 2002; Pang
et al., 2007; Tombran-Tink and Barnstable, 2003; Unterlauft et al.,
2012). Other tissues/cells including the brain, spinal cord, skeletal mus-
cle, heart, endothelial cells and osteoblasts also express PEDF (Akiyama
et al., 2010; Longeras et al., 2012; Rychli et al., 2010; Sanagi et al., 2010;
Tombran-Tink and Barnstable, 2003). In addition to putative anti-
angiogenic, anti-inﬂammatory, anti-oxidative and anti-tumorigenic
properties, PEDF is also neuroprotective for CNS neurons (Cao et al.,
1999; Dawson et al., 1999; Duh et al., 2002; Feng et al., 2013; Ho et al.,
2011; Zhang et al., 2006; Zhu and Zou, 2012). For example, in manyp, Neurobiology Section, School
and Dental Sciences, University
l Research (West), Edgbaston,
. This is an open access article underretinal pathologies, PEDF is secreted by reactive Müller cells and astro-
cytes and is neuroprotective for RGC and photoreceptors (Cao et al.,
2001; Lange et al., 2008; Li et al., 2006; Zhu and Zou, 2012).
Axotomised RGCs are not viable unless treated with neurotrophic
factors such as brain-derived neurotrophic factor, ciliary neurotrophic
factor and glial cell line-derived factor (Ahmed et al., 2006b; Benowitz
and Yin, 2007; Watanabe et al., 2003; Yip and So, 2000). Recently, we
conﬁrmed that, after optic nerve crush (ONC), PEDF is RGC neuroprotec-
tive and axogenic (Vigneswara et al., 2013), whilst other neuroprotec-
tive and anti-angiogenic N-terminal fragments of the native peptide
exist (Bilak et al., 2002; Gvritishvili et al., 2010; Li et al., 2006;
Mirochnik et al., 2009) including the neuroprotective amino acid resi-
dues 78–121, anti-angiogenic residues 16–26, 24–57, 44–77, 60–77
and 78–94 (Alberdi et al., 1999; Bilak et al., 2002; Filleur et al., 2005;
Liu et al., 2012) and residues 58–101 which promote the differentiation
of PC3 cells into neuro-secretory neurons (Filleur et al., 2005). Residues
78–101 constitute the PEDF-44 fragment, which is neuroprotective for
embryonic rat spinal motor neurons, whilst the PEDF-34 fragment, com-
prising residues 44–77 is not neuroprotective (Bilak et al., 2002). In this
study, we show that PEDF-34 is amore potent retinal neuron/RGC neuro-
protective/neuritogenic fragment than equimolar concentrations of PEDF-
44 in vitro. PEDF-34 was also more neuroprotective and axogenic in vivo,
after topical eye drop application compared to intravitreal injection.the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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2.1. Experimental design: in vitro experiments
For all in vitro experiments, adult 6–8-week-old female Sprague–
Dawley rats weighing 170–220 g were used. Culture experiments
included retinal cells treatedwith: (1), Neurobasal-A (NBA) alone (Con-
trol); and equimolar concentrations of (2), 2.16; (3) 5.4; (4), 10.8 and
(5), 21.6 pM PEDF-34/-44; and (6), ciliary neurotrophic factor (CNTF:
Peprotech, London, UK), as a positive control at an optimal neuroprotec-
tive/axogenic concentration of 440.5 pM, established by us previously
(Ahmed et al., 2009; Douglas et al., 2009). All treatments were added
to cultures on the following day (16–18 h after cell seeding) when
cells had adhered to the culture vessel. All experiments were performed
in triplicate and repeated on three independent occasions.
2.2. Experimental design: in vivo experiments
In the ﬁrst experiment, groups of 6 rats/treatment (i.e. 12 eyes/treat-
ment) were used to determine RGC survival by FluroGold (FG)
backﬁlling after weekly intravitreal PEDF-34 injections, comprising:
(1), intact; (2), ONC + vehicle (phosphate buffered saline (PBS); 0 nM
PEDF-34); (3), 0.268 nM PEDF-34; (4), 0.67 nM PEDF-34; (5), 1.34 nM
PEDF-34; (6), 1.88 nM PEDF-34 and (7) 2.68 nM PEDF-34. These equi-
molar concentrations were chosen since they are comparable to those
used in our previous study with full length PEDF (Vigneswara et al.,
2013). In a separate set of experiments comprising the same treatment
groups, 6 rats/treatment (i.e. 12 eyes/optic nerves/treatment) were
used to evaluate RGC axon regeneration by immunostaining with
growth-associated protein-43 (GAP-43) in the optic nerve.
To test the accumulation of PEDF-34 in the eye by western blot, 6
rats (12 eyes)/time point received pre-optimised 1.88 nM PEDF-34 by
a single eye drop onto the anterior surface of the eye and at 0.5, 4 and
24h after treatment, animalswere killed by risingCO2 levels and retinae
were harvested and analysed by western blot analysis. To conﬁrm the
accumulation of PEDF-34 in the eye by enzyme-linked immunosorbent
assay (ELISA), 6 animals (12 eyes)/time point/treatment were used to
analyse PEDF-34 levels in the vitreous and retina over the ﬁrst 24 h.
To test the accumulation of PEDF-34 in the vitreous and retina after
daily eye drop delivery, 6 animals (12 eyes)/day were used to analyse
the concentration of PEDF-34 by ELISA for a period of 28 days.
In further experiments, 12 rats (24 eyes/optic nerves)/treatment
received 1.88 nM PEDF-34 eye drops daily. Six rats (12 eyes)/
treatment were used to assess RGC survival at 21 days using FG
backﬁlling, whilst the remaining 6 rats (12 eyes/optic nerves)/
treatment were used to evaluate RGC axon regeneration at 21 days
by GAP-43 immunohistochemistry.
2.3. PEDF-34 synthesis
In initial experiments, PEDF-34was purchased from Phoenix Europe
GmbH, Karlsruhe, Germany but the majority of in vitro and in vivo
experiments were performed with in-house synthesised PEDF-34.
The PEDF-34 peptide spanning from amino acids 44 to 77 of the N-
terminus of the PEDF protein was chemically synthesised in a solid
phase peptide synthesiser, puriﬁed by HPLC and characterised by
mass spectrometry (Longeras et al., 2012). The similar activity of
commercially purchased compared to in-house synthesised PEDF-34
was conﬁrmed in retinal cultures.
2.4. Adult retinal cultures
Mixed adult rat retinal cultures containing enriched populations of
retinal neurons, including RGCs, were prepared from 6–8-week-old
adult female Sprague–Dawley rats, as described previously (Ahmed
et al., 2006b, 2009, 2010; Douglas et al., 2009; Vigneswara et al.,2013). Brieﬂy, retinal cells were dissociated using a Papain dissociation
kit according to the manufacturer's instructions (Worthington Bio-
chemicals, Lakewood, NJ, USA). Retinal cells were plated at a density
of 125 × 103/well in poly-D-lysine and laminin pre-coated 8-well cham-
ber slides and cultured in NBA supplemented with B27 supplement (all
from Invitrogen, Paisley, UK), with appropriate treatments for 4 days at
37 °C and 5% CO2 before ﬁxation in 4% paraformaldehyde diluted in PBS
for immunocytochemistry, as described previously (Vigneswara et al.,
2013, 2014).
2.5. Immunocytochemistry of retinal cultures
Fixed cells were washed in several changes of PBS before
permeabilisation and blocking of non-speciﬁc antibody sites with PBS
containing 3% bovine serum albumin (BSA) and 0.1% Triton X-100
(both from Sigma, Poole, UK). Cells were then incubated withmonoclo-
nal anti-βIII-tubulin antibody (1:200 dilution; Sigma) for 1 h at room
temperature (RT) to detect retinal neurons and their neurites. Cells
were then washed in several changes of PBS and incubated with Alexa
488 anti-mouse IgG (1:400 dilution; Invitrogen) for 1 h at RT. After
washing in several changes of PBS and mounting in Vectamount con-
taining DAPI (Vector Laboratories, Peterborough, UK), cells were then
viewed using a Zeiss epi-ﬂuorescent microscope equipped with an
AxioCam HRc and Axiovision Image capture software (all from Zeiss,
Hertfordshire, UK). Immunocytochemistry included controls with pri-
mary antibody omitted, to set background levels of nonspeciﬁc staining
(not shown) before image capture.
2.6. Retinal neuron survival and neurite outgrowth
The mean number of βIII-tubulin+ neurons surviving, with neurites
and the mean neurite length were quantiﬁed as described by us previ-
ously (Vigneswara et al., 2013, 2014). Brieﬂy, chamber slides were
anonymised by a second investigator and βIII-tubulin+ neuronal soma
and neurites quantiﬁed in 9 quadrants/well using Axiovision software
(Version 4.8; Zeiss) and ImagePro (Version 6.3; Media Cybernetics,
Bethesda, MD, USA). Of the 125,000 cells/well plated, the total numbers
of neurons in each experiment were determined by βIII-tubulin+ im-
munocytochemistry after allowing 30 min for cells to adhere to glass
culture slides. This determines the number of neurons plated/well and
is used in each experiment to work out the proportion of surviving
βIII-tubulin+ neurons. Neurite outgrowth from at least 180 neurons/
condition from the 9 wells was measured, except in control (NBA) cul-
tures, in which a total of 108 neurons were measured.
2.7. Optic nerve crush (ONC)
All animal procedures were licenced and approved by the United
Kingdom Home Ofﬁce and the University of Birmingham ethical review
committee and conformed to the Federation of European Laboratory
Animal Associations (FELASA) guidelines. Optic nerves were exposed
surgically in anaesthetised adult female Sprague–Dawley rats (170–
220 g) through a supraorbital approach and crushed bilaterally using
calibrated watchmakers forceps, 2 mm from the lamina cribrosa as de-
scribed by us previously (Vigneswara et al., 2013, 2014).
2.8. Intravitreal injections
Either PBS, or 0.268, 0.67, 1.34, 1.88, or 2.68 nM PEDF dissolved in
5 μl of sterile PBS was injected intravitreally immediately after ONC
(0 days) and repeated at 7 and 14 days after ONC with the same doses
of PEDF. None of the animals developed cataracts conﬁrming that the
lens had not been injured. Animals survived for 19 days before FG
back-labelling and killing by rising CO2 levels 2 days later, and eyes/
optic nerves harvested for retinal FG wholemounts. Further animals
Table 1
List of antibodies, their source and dilutions used in this study.
Antibody Host Source Use Dilution
Primary
βIII-Tubulin Mouse Sigma, Poole, UK IHC 1:200
PEDF Rabbit R&D Systems, Oxford, UK IHC/WB 1:400/1:500
GAP43 Mouse Invitrogen, Paisley, UK IHC 1:400
α-Tubulin Mouse Abcam, Cambridge, UK WB 1:1000
Secondary
Alexa 488 Goat Invitrogen, Paisley, UK IHC 1:400
Texas Red Donkey Invitrogen, Paisley, UK IHC 1:400
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34 and cryosectioned for immunohistochemistry.
2.9. Eye drops
Eye drops were formulated in 0.9% sterile saline as described previ-
ously and the samemolar concentrations delivered as for PEDF-34 used
for weekly intravitreal injections (Vigneswara et al., 2013). Animals
were lightly anaesthetised to prevent blinking and 5 μl of PEDF-34
with the pre-optimised 1.88 nM PEDF-34 was dropped onto the corne-
al/conjunctival surface daily for up to 28 days. To assess RGC survival
and axon regeneration, FG back-labelling was performed at 19 days
and animals were killed 2 days later by rising CO2 after which eyes
were harvested for retinal wholemounts. Further animals were killed
at 21 days after ONC and intravitreal PEDF-34 injections, killed by rising
CO2 levels and prepared for immunohistochemistry, western blot and
ELISA.
2.10. Retinal wholemounts
Nineteen days after ONC, FG (Cambridge Biosciences, Cambridge,
UK) was injected into the optic nerve, between the lamina cribrosa
and the ONC site (Vigneswara et al., 2013, 2014). Animals were killed
2 days later and the dissected retinae were immersion-ﬁxed in 4%
formaldehyde (TAAB Laboratories, Aldermaston, UK), ﬂattened onto
Superfrost Plus microscope slides (VWR International, Lutterworth,
UK) by making four equidistal radial cuts to obtain four quadrants, air
dried and mounted in Vectamount (Vector Laboratories). The identity
of individual retinae was anonymised by a second investigator before
image capture using a Zeiss epiﬂuorescent microscope and the number
of FG+ RGCs counted in ImagePro Version 6.0 (Media Cybernetics) from
captured images of 12 rectangular areas, 3 from each quadrant, placed
at radial distances from the centre of the optic disc of the inner (1/6
eccentricity), midperiphery (1/2 eccentricity) and outer retina (5/6 ec-
centricity). The mean densities of FG+ RGCs/mm2 for each retina were
determined.
2.11. Tissue preparation and sectioning for immunohistochemistry
Animals were killed with an overdose of CO2 and intracardially per-
fused with 4% formaldehyde, eyes and optic nerves were immersion
ﬁxed in 4% formaldehyde for a further 2 h before cryoprotection in a
graded series of sucrose. Eyes and optic nerves were embedded in
optimal cutting temperature (OCT) compound (Raymond A. Lamb,
Eastbourne, UK) and stored at −80 °C. Subsequently, 15 μm-thick
parasagittal eye or longitudinal optic nerve sections were cut using a
cryostat (Brights Instruments, Huntingdon, UK), adhered onto glass
slides and stored at−20 °C until required.
2.12. Immunohistochemistry
Immunohistochemistrywas performed as described by us previous-
ly (Vigneswara et al., 2013, 2014). Brieﬂy, sections were thawed,
washed at RT in PBS and permeabilised. Non-speciﬁc binding sites
were blocked in 3% bovine serum albumin (BSA) containing 0.1% Triton
X-100 and then sections were incubated in primary antibody diluted in
PBS containing 3% BSA and 0.05% Tween-20, overnight at 4 °C (16–
18 h). Monoclonal anti-GAP-43 antibody (1:500 dilution; Invitrogen)
stained regenerating axons in optic nerve sections (Table 1). Immuno-
histochemistry negative controls, in which the primary antibody was
omitted were included in each run and showed an absence of staining
(not shown). Sections were then washed in PBS and incubated with
either Alexa Fluor 488 or Texas Red-labelled secondary antibodies
(1:400 dilution; Invitrogen) for 1 h at RT, washed in PBS, mounted in
Vectamount containing DAPI (Vector Laboratories) and examined
with a Zeiss Axioplan 2 ﬂuorescent microscope, equipped with anAxioCamHRc camera andAxiovision software. Thenegative control sec-
tions were used to set the background threshold levels of ﬂuorescence
before image capture.2.13. Quantiﬁcation of axon regeneration
Regenerating axons in the optic nerve were quantiﬁed using previ-
ously published methods (Leon et al., 2000; Lorber et al., 2009;
Vigneswara et al., 2013, 2014). We did not use Cholera toxin B labelling
since GAP43 immunohistochemistry to detect regenerating axons is the
gold standard method in the rat. In addition, we have recently shown
that anterograde tracing with Rhodamine B in the rat is correlated
with the number of GAP43+ axons detected in both proximal and distal
areas after optic nerve crush, suggesting that both methods detect the
same regenerated axons (Vigneswara et al., 2014). Brieﬂy, an observer
blinded to the identity of the slides counted the number of axons ex-
tending beyond a vertical line at 250, 500, 1000, 1500, 2000 and
2500 μm distal to the lesion site in 8 longitudinal sections through
each nerve (n= 6 rats/12 optic nerves/treatment). Optic nerve diame-
ter was recorded using Axiovision Software (Zeiss) and the total num-
ber of axons per nerve extending distance d (Σad), in an optic nerve of
radius r calculated by summing over all sections with a thickness (t)
of 15 μm according to the following formula:
∑ad ¼ πr2  ðaverage axons mm−1Þ=t:2.14. Protein extraction and western blotting
Protein extraction and western blots were performed according to
our previously publishedmethods (Vigneswara et al., 2013, 2014). Brief-
ly, tissues from 6 rats/treatment (i.e. 12 retinae) were homogenised in
ice-cold lysis buffer (20 mM Tris, pH 7.4, 2 mM EDTA, 0.5 mM EGTA,
150 mM NaCl, 1% NP-40 and 5 μl/ml protease inhibitor cocktail) and
40 μg of total protein was resolved in 12% SDS gels, transferred to
polyvinylideneﬂuoridemembranes (Millipore,Watford, UK) andprobed
overnight at 4 °C with appropriate antibodies. Bands were detected with
HRP-labelled secondary antibodies (GE Healthcare, Buckinghamshire,
UK) using an enhanced chemiluminescence kit (GE Healthcare).2.15. Densitometry
Western blots were scanned into Adobe Photoshop (Adobe Systems
Inc., San Jose, CA, USA) keeping all scanning parameters the same be-
tween blots. Bands were then analysed using the built-in-macros for gel
analysis in ImageJ (NIH, USA, http://imagej.nih.gov/ij) and means ±
SEM plotted in Microsoft Excel (Microsoft Corporation, CA, USA)
(Ahmed et al., 2005, 2006a, 2011; Douglas et al., 2009). The integrated
density of each protein band in each lane was derived from 3 separate
blots from 3 independent experiments.
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Signiﬁcant differenceswere calculated between samplemeans using
GraphPad Prism (GraphPad Software Inc. Version 4.0, CA, San Diego,
USA) by one-way analysis of variance (ANOVA) followed by post-hoc
testingwith Dunnett's method and P b 0.05 was accepted as signiﬁcant.
3. Results
3.1. PEDF-34 promoted signiﬁcantly more neuron survival and neurite
outgrowth than PEDF-44
Both PEDF-34 and PEDF-44 promoted a dose-dependent increase in
βIII-tubulin+ neuron survival and neurite outgrowth (Fig. 1A–D), prob-
ably through both direct effects on retinal neurons and indirect effects
on other retinal cells. For example, the proportion of surviving βIII-
tubulin+ neurons in control untreated cultures was 18 ± 8%, whilstFig. 1. Retinal neuron survival and axon regeneration after exposure to PEDF-34 and PEDF-44. (
PEDF-44 and CNTF demonstrate that 5.4 pM of PEDF-34 and PEDF-44 optimally promotes neur
length also increased with increasing concentration of PEDF-34 and PEDF-44 with peak values
to demonstrate neurite outgrowth. *** = P b 0.0001; * = P b 0.05. Scale bars = 50 μm. Initial
wells 7–9 = 1387 neurons.the proportion of surviving βIII-tubulin+ neurons at the optimal con-
centration (5.4 pM) of PEDF-34 and PEDF-44 in cultures was 81 ± 8
and 44 ± 9%, respectively (Fig. 1A). CNTF (positive control) promoted
the survival of 30–34 ± 6% βIII-tubulin+ neurons after 4 days in
cultures. These results show that PEDF-34 treatment resulted in a 4.5-
fold increase in βIII-tubulin+ neuron numbers, whilst survival in CNTF
or PEDF-44-treated cultureswas 1.9- and 2.4-fold increased, respective-
ly, compared to untreated cultures.
Themean proportion of βIII-tubulin+ neuronswith neurites and the
mean neurite lengthwas optimal at 5.4 pM in PEDF-34 treated cultures,
reaching a maximum of 21 ± 2% βIII-tubulin+ neurons with neurites
(Fig. 1B) and a mean neurite length of 211 ± 23 μm (Fig. 1C and D).
With PEDF-44, the proportion of βIII-tubulin+ neurons with neurites
was 9 ± 1%, a response that peaked at 5.4 pM (Fig. 1B), whilst mean
neurite length peaked at 126 ± 7 μm at 10.8 pM (Fig. 1C and D).
PEDF-34 promoted 1.7-, 2.2- and 6.3-fold longer neurites and 2.3-,
10.5-, and 21-fold more βIII-tubulin+ neurons with neurites than inA) Retinal neuron proportions after incubationwith increasing concentrations of PEDF-34/
onal survival. (B) Themean proportion of neurons with neurites and (C) themean neurite
at 5.4 pM and 10.8 pM, respectively. (D) Representative images of βIII-tubulin+ neurons
βIII-tubulin+ retinal neuron plating density in wells 1–3 = 1350, wells 4–6 = 1337 and
216 V. Vigneswara et al. / Molecular and Cellular Neuroscience 68 (2015) 212–221PEDF-44, CNTF or untreated cultures. These results demonstrate that
PEDF-34 is signiﬁcantly more neuroprotective and neuritogenic than
PEDF-44, an effect that has not been previously described.
3.2. Intravitreal injection and eye drops of PEDF-34 promoted RGC survival
in vivo
We have already shown that intravitreal delivery, using the same
dosing regime (0, 7 and 14 days after ONC) and equimolar concentra-
tions of full length PEDF, promoted the survival of 55% of RGCs from
death at 21 days after ONC, whilst administration of CNTF after ONC
promoted limited RGC axon regeneration (Vigneswara et al., 2013).
Here we wished to conﬁrm that, in vivo, PEDF-34 was more neuro-
protective than full length PEDF. After intravitreal injection of
vehicle + 0 nM PEDF-34, 295 ± 15 FG+ RGC/mm2 survived 21 days
after ONC + PBS (0 nM PEDF-34) (Fig. 2A and B). Increasing the dose
of PEDF-34 caused a dose-dependent increase in the number of FG+
RGC surviving, achieving a maximum of 1720 ± 38 RGCs/mm2 using
1.88 nM. RGC survival did not improve by increasing the dose of
PEDF-34 to as much as 2.68 nM (Fig. 2A and B). These results show
that an intravitreal injection of an optimal dose of 1.88 nM PEDF-34
promoted 71% survival compared RGC numbers in intact controls.
We also investigated in the same experiment, if daily eye drops of
PEDF-34were effective in enhancing RGC survival at 21 days after ONC.
The number of FG+ RGCs counted in the control ONC + PBS-treatedFig. 2.Weekly intravitreal injection of PEDF-34- and daily eye drop-mediated RGC neuroprotec
andweekly intravitreal injections of 0, 0.268, 0.67, 1.34, 1.88 and 2.68 nMPEDF-34. (B) The num
Scale bars = 50 μm. ** = P b 0.001, *** = P b 0.0001.group was 292 ± 11 cells/mm2 (Fig. 2A and B). Increasing the concen-
tration of PEDF-34 in the eye drops increased the number of FG+
RGCs; a response that peaked at a concentration of 1.88 nM when the
number of surviving FG+ RGCs increased to 2110 ± 24 cells/mm2
(Fig. 2A and B), representing RGC survival of 87% compared to intact
controls. These results suggest that PEDF-34 eye drops were more effec-
tive at protecting RGCs from death after ONC than intravitreal injections.
3.3. PEDF-34 accumulated in the eye after delivery by eye drops
Small fragments of PEDF in vehicle, topically applied to the surface of
the eye enter into the vitreal chamber and access the retina (Liu et al.,
2012). We wished to establish if PEDF-34 accumulated in the posterior
chamber after delivery to the corneal/conjunctival surface by eye drops.
No changes in endogenous full-length PEDF were detected in the vitre-
ous using western blot and subsequent densitometry detected a 4.9-,
3.8- and 1.8-fold increase in PEDF-34 in both vitreous and retina after
delivery of the optimal 1.88 nM concentration of PEDF-34 by eye
drops after 0.5 h, 4 h and 24 h, respectively (Fig. 3A and B). However, lit-
tle or no changes in endogenous full-length PEDF were observed, and
little or no PEDF-34was detected in intact eyes (Fig. 3A). A positive con-
trol lane (10 μg of PEDF-34 peptide; Fig. 3A) indicated that the antibody
detected only changes in PEDF-34 and no other potential breakdown
products of PEDF were detected. These results demonstrated that after
eye drop delivery of PEDF-34: (1), the levels of endogenous full lengthtion is dose-dependent. (A) Representative images to show FG+ RGCs at 21 days after ONC
ber of FG+ RGCs present after delivery of different doses of PEDF-34 and in intact controls.
Fig. 3. PEDF-34 detection in the vitreous and the retina after topical application of an optimal 1.88 nM neuroprotective dose. (A) Representative full-length western blot showing no
changes in endogenous full length PEDF after a single delivery of PEDF-34 by eye dropswhilst PEDF-34 levels increasedwithin 30min then slowly reduced over thenext 24h.Also included
in a positive control lane, which contained 10 μg of PEDF-34. (B) Densitometry shows that PEDF-34 levels were 4.9-, 3.8- and 1.8-fold higher than the endogenous low levels of PEDF-34
seen in intact eyes, at 0.5, 4 and 24 h after a single administration of PEDF-34 eye drops. (C) Concentrations of PEDF detected by ELISA in the vitreous and the retina demonstrating a dose-
dependent increase in total PEDF at 0.5, 4 and 24 h after a single occasion eye drop delivery.
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predominantly recognises PEDF-34; and (3), that PEDF-34 accumulates
in the vitreous within 0.5 h and attain concentrations twice that of
untreated eyes after 24 h.
We also performed ELISAwith our polyclonal antibody to full length
PEDF to detect the levels of total PEDF in the vitreous and retina at 0.5, 4
and 24 h after application of a single eye drop dose. Since endogenous
full-length PEDF levels do not change, any measured changesmust cor-
respond to the accumulation of exogenous PEDF-34. ELISA in the retina
detected high levels of PEDF-34 and vitreous within 0.5 h, declining
slightly after 4 hwith a further decline at 24 h (Fig. 3C). For example, in-
creasing the concentrations of PEDF-34 in eye drops led to increased
levels of total PEDF in the vitreous and retina at 0.5 h, peaking with a
dose of 1.88 nM at 0.42 ± 0.01 nM and 0.18 ± 0.007 nM, respectively
(Fig. 3C). At 4 h, peak levels of total PEDF in the vitreous and retina
were 0.39± 0.004 nM and 0.24± 0.005 nM, whilst, at 24 h, peak levels
in the vitreous and retina were 0.21 ± 0.004 nM and 0.12 ± 0.002 nM,
respectively (Fig. 3C). These data conﬁrm that high concentrations of
PEDF-34 accumulate in the posterior chamber of the eye after topical
eye drop application.
We next investigated whether eye drops prepared with the optimal
concentration of PEDF-34 of 1.88 nM, when applied daily, couldmaintain high levels of PEDF-34 in the vitreous and retina for 28 days.
Eyes receiving eye drops were carefully monitored with an ophthalmo-
scope for signs of corneal reactions to PEDF-34, including redness, in-
ﬂammation or opacity throughout the duration of the experiment.
None of the PEDF-34 treated eyes exhibited any of these symptoms.
Daily PEDF-34 eye drops induced a gradual increase in the levels of
PEDF-34 in both the vitreous and the retina over the ﬁrst 7 days
which peaked at 14 days to 1.4 ± 0.045 nM and 0.65 ± 0.025 nM,
respectively (Fig. 4). After extending the treatments for 28 days, no fur-
ther increase in the level of PEDF-34was apparent in either the vitreous
or retina (Fig. 4). These results suggest that levels of PEDF-34 gradually
increase in the vitreous and retina over the ﬁrst 14 days to a plateau
level, which is maintained thereafter with continued eye drops.
3.4. Daily eye drops of PEDF-34 promoted more RGC axon regeneration
than weekly intravitreal injections of PEDF-34
FewGAP-43+ axonswere observed at 21 days after ONC in the prox-
imal optic nerve stump of control eyes treated with PBS eye drops and
only 56± 11 and 44± 4were present at 250 and 500 μm, respectively,
beyond the lesion site and in the distal stump (Fig. 5A and D). After
weekly intravitreal delivery of the optimal 1.88 nM concentration of
Fig. 4. PEDF-34 levels in the vitreous and retina monitored by ELISA over 28 days after
daily eye drop application of the optimal 1.88 nM neuroprotective dose. The levels of
total PEDF (full length and fragments) in the vitreous and retina increased over time to
a peak at 14 days, after which a plateau in concentration was reached despite continued
eye drop application.
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stump, whilst 2038 ± 234, 1733 ± 237, 1462 ± 175, 945 ± 100 and
79 ± 44 axons grew up to 200, 500, 1000, 1500 and 2000 μm from the
lesion site, respectively, into the distal optic nerve stump (Fig. 5B andFig. 5.Weekly intravitreal injections and daily eye drop application of PEDF-34 promote
RGC axon regeneration at 21 days after ONC. Representative GAP-43+ immunohistochem-
istry to show axons growing in the optic nerve after (A), ONC + PBS, (B), ONC + weekly
intravitreal injections of PEDF-34 and (C), ONC + daily eye drops of PEDF-34 (scale
bars= 100 μm). (D) Quantiﬁcation of the number of GAP-43+ axons growing in the distal
optic nerve stump at 250, 500, 1000, 1500, 2000 and 2500 μm from the lesion centre.
* = P b 0.05, *** = P b 0.0001, ivit = intravitreal. Red arrow = lesion epicentre.D). However, the greatest number of RGC axons was observed in the
optic nerve of the PEDF-34 eye drop-treated groups when 4049 ±
355, 2893 ± 315, 2043 ± 120, 1285 ± 126, 884 ± 139, 582 ± 155
axons were present at 200, 500, 1000, 1500, 2000, and 2500 μm distal
from the lesion site, respectively (Fig. 5C and D). These results demon-
strated that over a period of 21 days, daily PEDF-34 eye drops were
more axogenic (P b 0.0001) than weekly intravitreal injections of equi-
molar concentrations of PEDF-34.
4. Discussion
In the present study, we demonstrate that PEDF-34 is both neuro-
protective and axogenic in vitro and in vivo for adult rat retinal neu-
rons/RGCs. PEDF-34 is also more effective in promoting RGC survival
and axon regeneration compared to full-length PEDF or PEDF-44. De-
livery of PEDF-34 by eye drops protected 87% of RGCs from death
after ONC, whilst weekly intravitreal injection of PEDF-34 supported
71% of RGCs from death. Daily PEDF-34 eye drops also promoted the
regeneration of more RGC axons than did weekly intravitreal injec-
tions. In addition, daily eye drop delivery of PEDF-34 is detected in
the vitreous within 0.5 h and accumulates in there and in the retina
in high concentrations by 5 h and reaches a plateau of concentration
at 14 days, when further eye drop applications maintain but do not
increase levels of PEDF-34. Thus, daily eye drops of PEDF-34 are
more RGC neuroprotective and axogenic compared to weekly intra-
vitreal PEDF-34 injections.
Our results with PEDF-34 on retinal neuron/RGC protection do not
substantiate those of Bilak et al. (2002), a condition that may be ex-
plained by differences in the neuronal phenotypes used, i.e. embryonic
day 16 motor neurons used by Bilak et al. (2002), whilst we cultured
adult sensory neurons in this current study. It is also well recognised
that embryonic neurons behave differently to adult neurons and one
signiﬁcant factor in our observed effects of PEDF-34 on adult retinal
neuron/RGC neuroprotection and axon regeneration might be that cy-
clic adenosine monophosphate (cAMP) levels are attenuated in adult
neurons whilst embryonic neurons require neurotrophic factors for
their survival. The same PEDF-34 sequence was also reported by others
to be non-neurotrophic and anti-angiogenic by (Alberdi et al., 1999;
Filleur et al., 2005). However, our current study shows that PEDF-34 is
highly neuroprotective and axogenic to adult rat retinal neuron/RGC
both in vitro and in vivo and is also more potent than the currently ac-
cepted neurotrophic fragment of PEDF, PEDF-44 (Bilak et al., 2002;
Filleur et al., 2005). Moreover, we do not yet know why PEDF-34 was
better than PEDF-44 in terms of neuroprotection and RGC neurite out-
growth but this is currently under investigation. PEDF-34 and PEDF-44
appeared to be equally stable in culturemedia and retained their neuro-
trophic properties after long-term storage. It is also not knownwhether
PEDF-34 and PEDF-44 bind different receptors, however furtherwork in
this area would help clarify these issues.
The mechanism of enhanced retinal neuron/RGC survival after
PEDF-34 treatment is unknown, although exogenous PEDF-34 may
down regulate the apoptotic genes caspase-2, calpain andmitogen acti-
vated protein kinase (MAPK)-1 after binding to one or more the high
afﬁnity PEDF receptors, stimulating downstream phospholipase A2
enzymatic activity (Tombran-Tink and Barnstable, 2003). Inhibition of
both nuclear kappa-light-chain-enhancer of activated B cell (NFκB)
and extracellular signal-related kinase (ERK)-1/2 pathways abrogates
the protective effects of PEDF in cultured retinal neurons, suggesting
that theNFκB and ERK1/2 pathways activated by PEDFmaymediate ret-
inal neuron/RGC neuroprotection (Pang et al., 2007; Tombran-Tink,
2005; Tombran-Tink and Barnstable, 2003). Activation of the NFκB
pathway induces the expression of brain-derived neurotrophic factor
(BDNF), nerve growth factor (NGF), B-cell lymphoma-extra large and
superoxide dismutase (Courtois, 2005; Wu and Kral, 2005), whilst
PEDF activated ERK1/2 modulates kinases, phosphatases, transcription
factors and regulators of apoptosis (Rubinfeld and Seger, 2005; Yoon
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hanced retinal neuron/RGC survival may also be facilitated indirectly
by retinal glia and other neurons since our retinal cultures contained
mixed retinal cells. However, we have previously characterised our
cultures and shown that activated glia, which secrete additional neuro-
trophic factors, were absent in our retinal cultures (Suggate et al., 2009)
and therefore we expect the contribution of indirect effects on retinal
glia and other neurons to be minimal as opposed to the direct effects
of PEDF-34 on retinal neurons/RGCs.
Both extrinsic and intrinsic factors regulate axon sprouting and
elongation supported by the observation that PEDF is included among
the neurotrophic factors that activate the ras–raf–MAPK and the
phosphoinositide 3-kinase (PI3K)–protein kinase B (Akt) signalling
pathways which are both axogenic (Koeberle and Ball, 2002). Five-
fold more retinal neuron/RGC neuritogenesis/axogenesis was stimulat-
ed by PEDF-34 when compared to untreated controls, conﬁrming that
PEDF-34 is a potent axogenic factor. Inhibiting apoptosis after either
Bax knockout or overexpression of Bcl-2, whilst suppressing either
MAPK or PI3K, partially arrests axon regeneration, whilst inhibiting
both together, completely suppresses axon elongation (Mo et al.,
2002). Conversely, stimulating either the PI3K or Akt pathways in-
creases axon thickness and branching whilst blocking raf, PI3K and
Akt suppresses cAMP potentiated axon outgrowth (Mo et al., 2002).
Although we showed that secreted retinal glia-derived PEDF may
supplement endogenous titres of PEDF (Vigneswara et al., 2012),
exogenous PEDF-34 delivery does not affect endogenous levels of full
length PEDF and thus retinal glia-derived PEDF does not contribute to
the enhanced retinal neuron/RGC neuroprotection and axogenesis ob-
served in our current study. Although PEDF is constitutively expressed
by pigment, ciliary and corneal epithelial cells and also by Müller glia,
retinal astrocytes and neurons/RGC, the levels of PEDF are generally
low. Furthermore, we detected a weak band correlating to PEDF-34 in
intact retina, suggesting that PEDF-34 may naturally be present in low
amounts but this has never been reported by others and requires fur-
ther investigation. Therefore, exogenous PEDF-34 delivery, especially
through the use of eye drops is potentially a non-invasive, therapeuti-
cally advantageous strategy to promote RGC survival and axon regener-
ation. It is widely accepted that different signalling pathways regulate
neuron survival and axon regeneration since both responses can be
isolated. For example, we have shown previously that intravitreal and
intra-optic nerve inﬂammation is retinal neuron/RGC protective but
only the former promotes axon regeneration (Ahmed et al., 2010).
Therefore, one particular advantage of PEDF-34 is that both retinal neu-
ron/RGC survival and axon regeneration are signiﬁcantly promoted, im-
plying that multiple axon growth and survival pathways are activated
by PEDF-34.
Other commonly used retinal neuron/RGC neuroprotective factors
include BDNF, glial-derived neurotrophic factor (GDNF), neurotrophin
(NT)-3, NT-4/5, as well as caspase inhibitors (Cheng et al., 2002;
Kermer et al., 1998; Kurokawa et al., 1999; Monnier et al., 2011;
Parrilla-Reverter et al., 2009). Although intravitreal injections of BDNF
protect 100% of RGC for 7 days, efﬁciency declines to 60% by 21 days.
Most neuroprotective strategies tested support the survival of a
maximum of 60% of RGC at 2 weeks after injury (Cheng et al., 2002;
Kermer et al., 1998; Kurokawa et al., 1999; Monnier et al., 2011;
Parrilla-Reverter et al., 2009) whilst combinations of agents such as
GDNF+BDNF and BDNF+ Tropomysin receptor kinase (Trk)B support
up to 80% RGC survival, but very few of these combinations of neuro-
trophic factors support signiﬁcantly greater axon regeneration than
that obtained with CNTF. PEDF promotes more survival of retinal neu-
ron/RGC in vitro and in vivo than any other neurotrophic factor thus
far reported, and is also one of the most retinal neuron/RGC axogenic
factors.
Drug administration to the retina and vitreous body is challenging.
Drugs applied to the surface of the eye rarely penetrate the ocular sur-
face or enter into the vitreous body and the retina (Gaudana et al.,2010). Biological barriers such as the cornea, conjunctiva and the tear
ﬁlm limit penetration and bioavailability of topical drug preparations
to the posterior segment of the eye and therefore direct injection of
drugs to the vitreous is commonly used to target drugs to the retina
(Ayalasomayajula and Kompella, 2005; Carneiro et al., 2009; Eldaly
and Styles, 2009; Yasukawa et al., 2001) but has the risk of signiﬁcant
complications including cataracts, vitreous haemorrhages and retinal
detachment. There are several colloidal drug delivery systems such as li-
posomes (Hathout et al., 2007; Kaur et al., 2004; Law et al., 2000),
niosomes (Abdelbary and El-Gendy, 2008), nanoparticles (Agnihotri
and Vavia, 2009) and nanoemulsions (Badawi et al., 2008) that enhance
bioavailability of drugs to the retina after eye drop administration. For
example, modiﬁed liposomes made from poly-L-lysine, are cationic
and effectively deliver peptides to the back of the eye (Makhlof et al.,
2011;Murata et al., 2012), butwhether therapeutic proteins or peptides
reach the posterior segment of the eye is controversial. However, after
delivery of insulin (5.8 kDa) by eye drops combined with a penetration
enhancer, insulin is localised to the Lewis rat retina and accumulates
in the optic nerve (Koevary et al., 2002). In adult rats, high levels of
125I-labelled nerve growth factor (26 kDa) accumulates in the retina
and optic nerve peaking at 6 h after topical administration (Lambiase
et al., 2005).
Antibody fragments (28 kDa) also penetrate into the rabbit vitreous
(Williams et al., 2005), whilst ESBA105, an anti-tumour necrosis factor
single-chain antibody (26 kDa) reaches the retina after topical adminis-
tration in New Zealand rabbit eyes without the use of penetration
enhancers (Furrer et al., 2009). In this latter study, topical delivery of
ESBA105 was advantageous over intra-vein injections achieving 25-
fold higher drug levels, suggesting that an anterior trans-scleral passage
of the drug may have occurred without trans-corneal passage (Furrer
et al., 2009). Our result with 3.7 kDa PEDF-34 is entirely consistent
with the above reports and suggests that PEDF-34 passes into the poste-
rior chamber without the need for drug carriers and accumulates in the
vitreous quickly and efﬁciently (within 30 min), achieving high retinal
concentrations by 4 h. The diffusion of PEDF-34 is partly due to the
small size of this sequence, it's hydrophilic nature and it's daily admin-
istration. PEDF-34 would therefore diffuse through the cornea and the
subconjunctiva and probably through diffusion into ocular surface
vasculature, all of which will facilitate the transport of PEDF-34 into
the retina. Indeed, a 2.1 kDa fragment, labelled with ﬂuorescein was
localised throughout the cornea and reached therapeutic levels into
the retina after 4 h (Liu et al., 2012).
As indicated, topically applied PEDF-34 peptide may reach the
posterior chamber through multiple routes, including diffusion
through the cornea and conjunctiva since the cornea and conjunctiva
were intensely positive for ﬂuorescein-labelled PEDF (Liu et al.,
2012). PEDF-34 may also diffuse into ocular surface blood vessels,
thereby passing into the RPE-choroid and inner retina vasculature
(Liu et al., 2012). As for why PEDF-34 eye drops should be better
than intravitreal injections of PEDF-34 remains to be investigated.
We suspect that this may be due to the fact that intravitreal injection
delivers a bolus of PEDF-34 that may have beneﬁcial neuroprotective
and axogenic properties in the eye prior to its clearance before the
next injection. However, since eye drops are administered daily,
this sustains maximal neuroprotective and axogenic properties
throughout the time of its administration. Eye drops of PEDF-34
therefore counter the natural ONC injury-related deleterious effects
observed.
In conclusion, contrary to early reports that PEDF-34 is not neuro-
protective, we demonstrate that PEDF-34 is more retinal neuron/RGC
neuroprotective and axogenic than either full-length PEDF or PEDF-44.
Moreover, the potent retinal neuron/RGC protective and axogenic
effects of eye drops comprising PEDF-34 have potential, non-invasive
convenient and more effective use than intravitreal injections in the
treatment of neuropathies and diseases of the eye featuring retinal
neuron/RGC death, such as glaucoma.
220 V. Vigneswara et al. / Molecular and Cellular Neuroscience 68 (2015) 212–221Acknowledgements/disclosures
This work was funded by the Wellcome Trust Grant no. 092539/Z/
10/Z (ZA).
All authors declare no ﬁnancial disclosures.References
Abdelbary, G., El-Gendy, N., 2008. Niosome-encapsulated gentamicin for ophthalmic
controlled delivery. AAPS PharmSciTech 9, 740–747.
Agnihotri, S.M., Vavia, P.R., 2009. Diclofenac-loaded biopolymeric nanosuspensions for
ophthalmic application. Nanomedicine 5, 90–95.
Ahmed, Z., Dent, R.G., Suggate, E.L., Barrett, L.B., Seabright, R.J., Berry, M., Logan, A., 2005.
Disinhibition of neurotrophin-induced dorsal root ganglion cell neurite outgrowth on
CNS myelin by siRNA-mediated knockdown of NgR, p75NTR and Rho-A. Mol. Cell.
Neurosci. 28, 509–523.
Ahmed, Z., Mazibrada, G., Seabright, R.J., Dent, R.G., Berry, M., Logan, A., 2006a. TACE-
induced cleavage of NgR and p75(NTR) in dorsal root ganglion cultures disinhibits
outgrowth and promotes branching of neurites in the presence of inhibitory CNS
myelin. FASEB J. 20, 1939-+.
Ahmed, Z., Suggate, E.L., Brown, E.R., Dent, R.G., Armstrong, S.J., Barrett, L.B., Berry,
M., Logan, A., 2006b. Schwann cell-derived factor-induced modulation of the
NgR/p75NTR/EGFR axis disinhibits axon growth through CNS myelin in vivo
and in vitro. Brain 129, 1517–1533.
Ahmed, Z., Berry, M., Logan, A., 2009. ROCK inhibition promotes adult retinal ganglion cell
neurite outgrowth only in the presence of growth promoting factors. Mol. Cell.
Neurosci. 42, 128–133.
Ahmed, Z., Aslam, M., Lorber, B., Suggate, E.L., Berry, M., Logan, A., 2010. Optic nerve and
vitreal inﬂammation are both RGC neuroprotective but only the latter is RGC
axogenic. Neurobiol. Dis. 37, 441–454.
Ahmed, Z., Kalinski, H., Berry, M., Almasieh, M., Ashush, H., Slager, N., Brafman, A., Spivak,
I., Prasad, N., Mett, I., Shalom, E., Alpert, E., Di Polo, A., Feinstein, E., Logan, A., 2011.
Ocular neuroprotection by siRNA targeting caspase-2. Cell Death Dis. 2, e173.
Akiyama, T., Dass, C.R., Shinoda, Y., Kawano, H., Tanaka, S., Choong, P.F., 2010. PEDF regu-
lates osteoclasts via osteoprotegerin and RANKL. Biochem. Biophys. Res. Commun.
391, 789–794.
Alberdi, E., Aymerich, M.S., Becerra, S.P., 1999. Binding of pigment epithelium-derived
factor (PEDF) to retinoblastoma cells and cerebellar granule neurons. Evidence for a
PEDF receptor. J. Biol. Chem. 274, 31605–31612.
Ayalasomayajula, S.P., Kompella, U.B., 2005. Subconjunctivally administered celecoxib–
PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxida-
tive stress in a rat model. Eur. J. Pharmacol. 511, 191–198.
Badawi, A.A., El-Laithy, H.M., El Qidra, R.K., El Mofty, H., El dally, M., 2008. Chitosan based
nanocarriers for indomethacin ocular delivery. Arch. Pharm. Res. 31, 1040–1049.
Barnstable, C.J., Tombran-Tink, J., 2004. Neuroprotective and antiangiogenic actions of
PEDF in the eye: molecular targets and therapeutic potential. Prog. Retin. Eye Res.
23, 561–577.
Benowitz, L.I., Yin, Y., 2007. Combinatorial treatments for promoting axon regeneration in
the CNS: strategies for overcoming inhibitory signals and activating neurons' intrinsic
growth state. Dev. Neurobiol. 67, 1148–1165.
Bilak, M.M., Becerra, S.P., Vincent, A.M., Moss, B.H., Aymerich, M.S., Kuncl, R.W., 2002.
Identiﬁcation of the neuroprotective molecular region of pigment epithelium-
derived factor and its binding sites on motor neurons. J. Neurosci. 22, 9378–9386.
Cao, W., Tombran-Tink, J., Chen, W., Mrazek, D., Elias, R., McGinnis, J.F., 1999. Pigment
epithelium-derived factor protects cultured retinal neurons against hydrogen
peroxide-induced cell death. J. Neurosci. Res. 57, 789–800.
Cao, W., Tombran-Tink, J., Elias, R., Sezate, S., Mrazek, D., McGinnis, J.F., 2001. In vivo
protection of photoreceptors from light damage by pigment epithelium-derived
factor. Invest. Ophthalmol. Vis. Sci. 42, 1646–1652.
Carneiro, A., Falcao, M., Pirraco, A., Milheiro-Oliveira, P., Falcao-Reis, F., Soares, R., 2009.
Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal
dose range on endothelial cells. Exp. Eye Res. 88, 522–527.
Cheng, L., Sapieha, P., Kittlerova, P., Hauswirth, W.W., Di Polo, A., 2002. TrkB gene transfer
protects retinal ganglion cells from axotomy-induced death in vivo. J. Neurosci. 22,
3977–3986.
Courtois, G., 2005. The NF-kappaB signaling pathway in human genetic diseases. Cell. Mol.
Life Sci. 62, 1682–1691.
Dawson, D.W., Volpert, O.V., Gillis, P., Crawford, S.E., Xu, H., Benedict, W., Bouck, N.P.,
1999. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science
285, 245–248.
Douglas, M.R., Morrison, K.C., Jacques, S.J., Leadbeater, W.E., Gonzalez, A.M., Berry, M.,
Logan, A., Ahmed, Z., 2009. Off-target effects of epidermal growth factor receptor
antagonists mediate retinal ganglion cell disinhibited axon growth. Brain 132,
3102–3121.
Duh, E.J., Yang, H.S., Suzuma, I., Miyagi, M., Youngman, E., Mori, K., Katai, M., Yan, L.,
Suzuma, K., West, K., Davarya, S., Tong, P., Gehlbach, P., Pearlman, J., Crabb, J.W.,
Aiello, L.P., Campochiaro, P.A., Zack, D.J., 2002. Pigment epithelium-derived factor
suppresses ischemia-induced retinal neovascularization and VEGF-induced migra-
tion and growth. Invest. Ophthalmol. Vis. Sci. 43, 821–829.
Eldaly, M.A., Styles, C., 2009. First versus second eye intravitreal ranibizumab therapy for
wet AMD. Retina 29, 325–328.
Feng, C.C., Wang, P.H., Ding, Q., Guan, M., Zhang, Y.F., Jiang, H.W., Wen, H., Wu, Z., 2013.
Expression of pigment epithelium-derived factor and tumor necrosis factor-alpha iscorrelated in bladder tumor and is related to tumor angiogenesis. Urol. Oncol. 31,
241–246.
Filleur, S., Volz, K., Nelius, T., Mirochnik, Y., Huang, H., Zaichuk, T.A., Aymerich, M.S.,
Becerra, S.P., Yap, R., Veliceasa, D., Shroff, E.H., Volpert, O.V., 2005. Two functional
epitopes of pigment epithelial-derived factor block angiogenesis and induce differen-
tiation in prostate cancer. Cancer Res. 65, 5144–5152.
Furrer, E., Berdugo, M., Stella, C., Behar-Cohen, F., Gurny, R., Feige, U., Lichtlen, P., Urech,
D.M., 2009. Pharmacokinetics and posterior segment biodistribution of ESBA105, an
anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye.
Invest. Ophthalmol. Vis. Sci. 50, 771–778.
Gaudana, R., Ananthula, H.K., Parenky, A., Mitra, A.K., 2010. Ocular drug delivery. AAPS J.
12, 348–360.
Gvritishvili, A.G., Leung, K.W., Tombran-Tink, J., 2010. Codon preference optimization
increases heterologous PEDF expression. PLoS One 5, e15056.
Hathout, R.M., Mansour, S., Mortada, N.D., Guinedi, A.S., 2007. Liposomes as an ocular de-
livery system for acetazolamide: in vitro and in vivo studies. AAPS PharmSciTech 8, 1.
Ho, T.C., Chen, S.L., Shih, S.C., Chang, S.J., Yang, S.L., Hsieh, J.W., Cheng, H.C., Chen, L.J., Tsao,
Y.P., 2011. Pigment epithelium-derived factor (PEDF) promotes tumor cell death by
inducing macrophage membrane tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL). J. Biol. Chem. 286, 35943–35954.
Karakousis, P.C., John, S.K., Behling, K.C., Surace, E.M., Smith, J.E., Hendrickson, A., Tang,
W.X., Bennett, J., Milam, A.H., 2001. Localization of pigment epithelium derived factor
(PEDF) in developing and adult human ocular tissues. Mol. Vis. 7, 154–163.
Kaur, I.P., Garg, A., Singla, A.K., Aggarwal, D., 2004. Vesicular systems in ocular drug deliv-
ery: an overview. Int. J. Pharm. 269, 1–14.
Kermer, P., Klocker, N., Labes, M., Bahr, M., 1998. Inhibition of CPP32-like proteases
rescues axotomized retinal ganglion cells from secondary cell death in vivo.
J. Neurosci. 18, 4656–4662.
Koeberle, P.D., Ball, A.K., 2002. Neurturin enhances the survival of axotomized retinal gan-
glion cells in vivo: combined effects with glial cell line-derived neurotrophic factor
and brain-derived neurotrophic factor. Neuroscience 110, 555–567.
Koevary, S.B., Nussey, J., Lake, S., 2002. Accumulation of topically applied porcine insulin
in the retina and optic nerve in normal and diabetic rats. Invest. Ophthalmol. Vis.
Sci. 43, 797–804.
Kurokawa, T., Katai, N., Shibuki, H., Kuroiwa, S., Kurimoto, Y., Nakayama, C., Yoshimura, N.,
1999. BDNF diminishes caspase-2 but not c-Jun immunoreactivity of neurons in ret-
inal ganglion cell layer after transient ischemia. Invest. Ophthalmol. Vis. Sci. 40,
3006–3011.
Lambiase, A., Tirassa, P., Micera, A., Aloe, L., Bonini, S., 2005. Pharmacokinetics of
conjunctivally applied nerve growth factor in the retina and optic nerve of adult
rats. Invest. Ophthalmol. Vis. Sci. 46, 3800–3806.
Lange, J., Yafai, Y., Reichenbach, A., Wiedemann, P., Eichler, W., 2008. Regulation of
pigment epithelium-derived factor production and release by retinal glial (Muller)
cells under hypoxia. Invest. Ophthalmol. Vis. Sci. 49, 5161–5167.
Law, S.L., Huang, K.J., Chiang, C.H., 2000. Acyclovir-containing liposomes for potential
ocular delivery. Corneal penetration and absorption. J. Control. Release 63, 135–140.
Leon, S., Yin, Y., Nguyen, J., Irwin, N., Benowitz, L.I., 2000. Lens injury stimulates axon
regeneration in the mature rat optic nerve. J. Neurosci. 20, 4615–4626.
Li, H., Tran, V.V., Hu, Y., Mark Saltzman,W., Barnstable, C.J., Tombran-Tink, J., 2006. A PEDF
N-terminal peptide protects the retina from ischemic injury when delivered in PLGA
nanospheres. Exp. Eye Res. 83, 824–833.
Liu, Y., Leo, L.F., McGregor, C., Grivitishvili, A., Barnstable, C.J., Tombran-Tink, J., 2012. Pig-
ment epithelium-derived factor (PEDF) peptide eye drops reduce inﬂammation, cell
death and vascular leakage in diabetic retinopathy in Ins2(Akita) mice. Mol. Med. 18,
1387–1401.
Longeras, R., Farjo, K., Ihnat, M., Ma, J.X., 2012. A PEDF-derived peptide inhibits retinal
neovascularization and blocks mobilization of bone marrow-derived endothelial
progenitor cells. Exp. Diabetes Res. 518426.
Lorber, B., Howe, M.L., Benowitz, L.I., Irwin, N., 2009. Mst3b, an Ste20-like kinase, regulates
axon regeneration in mature CNS and PNS pathways. Nat. Neurosci. 12, 1407–1414.
Makhlof, A., Fujimoto, S., Tozuka, Y., Takeuchi, H., 2011. In vitro and in vivo evaluation of
WGA–carbopol modiﬁed liposomes as carriers for oral peptide delivery. Eur. J. Pharm.
Biopharm. 77, 216–224.
Mirochnik, Y., Aurora, A., Schulze-Hoepfner, F.T., Deabes, A., Shifrin, V., Beckmann, R.,
Polsky, C., Volpert, O.V., 2009. Short pigment epithelial-derived factor-derived pep-
tide inhibits angiogenesis and tumor growth. Clin. Cancer Res. 15, 1655–1663.
Mo, X., Yokoyama, A., Oshitari, T., Negishi, H., Dezawa, M., Mizota, A., Adachi-Usami, E.,
2002. Rescue of axotomized retinal ganglion cells by BDNF gene electroporation in
adult rats. Invest. Ophthalmol. Vis. Sci. 43, 2401–2405.
Monnier, P.P., D'Onofrio, P.M., Magharious, M., Hollander, A.C., Tassew, N., Szydlowska, K.,
Tymianski, M., Koeberle, P.D., 2011. Involvement of caspase-6 and caspase-8 in
neuronal apoptosis and the regenerative failure of injured retinal ganglion cells.
J. Neurosci. 31, 10494–10505.
Murata, M., Nakano, K., Tahara, K., Tozuka, Y., Takeuchi, H., 2012. Pulmonary delivery of
elcatonin using surface-modiﬁed liposomes to improve systemic absorption: polyvi-
nyl alcohol with a hydrophobic anchor and chitosan oligosaccharide as effective
surface modiﬁers. Eur. J. Pharm. Biopharm. 80, 340–346.
Ogata, N.,Wada, M., Otsuji, T., Jo, N., Tombran-Tink, J., Matsumura, M., 2002. Expression of
pigment epithelium-derived factor in normal adult rat eye and experimental choroi-
dal neovascularization. Invest. Ophthalmol. Vis. Sci. 43, 1168–1175.
Pang, I.H., Zeng, H., Fleenor, D.L., Clark, A.F., 2007. Pigment epithelium-derived factor
protects retinal ganglion cells. BMC Neurosci. 8, 11.
Parrilla-Reverter, G., Agudo, M., Sobrado-Calvo, P., Salinas-Navarro, M., Villegas-Perez,
M.P., Vidal-Sanz, M., 2009. Effects of different neurotrophic factors on the survival
of retinal ganglion cells after a complete intraorbital nerve crush injury: a quantita-
tive in vivo study. Exp. Eye Res. 89, 32–41.
221V. Vigneswara et al. / Molecular and Cellular Neuroscience 68 (2015) 212–221Rubinfeld, H., Seger, R., 2005. The ERK cascade: a prototype of MAPK signaling. Mol.
Biotechnol. 31, 151–174.
Rychli, K., Kaun, C., Hohensinner, P.J., Dorfner, A.J., Pfaffenberger, S., Niessner, A., Bauer, M.,
Dietl, W., Podesser, B.K., Maurer, G., Huber, K., Wojta, J., 2010. The anti-angiogenic
factor PEDF is present in the human heart and is regulated by anoxia in cardiac
myocytes and ﬁbroblasts. J. Cell. Mol. Med. 14, 198–205.
Sanagi, T., Yabe, T., Yamada, H., 2010. Adenoviral gene delivery of pigment epithelium-
derived factor protects striatal neurons from quinolinic acid-induced excitotoxicity.
J. Neuropathol. Exp. Neurol. 69, 224–233.
Suggate, E.L., Ahmed, Z., Read, M.L., Eaton-Charnock, K., Douglas, M.R., Gonzalez, A.M.,
Berry, M., Logan, A., 2009. Optimisation of siRNA-mediated RhoA silencing in neuro-
nal cultures. Mol. Cell. Neurosci. 40, 451–462.
Tombran-Tink, J., 2005. The neuroprotective and angiogenesis inhibitory serpin, PEDF:
new insights into phylogeny, function, and signaling. Front. Biosci. 10, 2131–2149.
Tombran-Tink, J., Barnstable, C.J., 2003. PEDF: a multifaceted neurotrophic factor. Nat.
Rev. Neurosci. 4, 628–636.
Unterlauft, J.D., Eichler, W., Kuhne, K., Yang, X.M., Yafai, Y., Wiedemann, P.,
Reichenbach, A., Claudepierre, T., 2012. Pigment epithelium-derived factor re-
leased by Muller glial cells exerts neuroprotective effects on retinal ganglion
cells. Neurochem. Res. 37, 1524–1533.
Vigneswara, V., Berry, M., Logan, A., Ahmed, Z., 2012. Pharmacological inhibition of
caspase-2 protects axotomised retinal ganglion cells from apoptosis in adult rats.
PLoS One 7, e53473.
Vigneswara, V., Berry,M., Logan, A., Ahmed, Z., 2013. Pigment epithelium-derived factor is
retinal ganglion cell neuroprotective and axogenic after optic nerve crush injury.
Invest. Ophthalmol. Vis. Sci. 54, 2624–2633.Vigneswara, V., Akpan, N., Berry, M., Logan, A., Troy, C.M., Ahmed, Z., 2014. Combined
suppression of CASP2 and CASP6 protects retinal ganglion cells from apoptosis and
promotes axon regeneration through CNTF-mediated JAK/STAT signalling. Brain
137, 1656–1675.
Watanabe, M., Tokita, Y., Kato, M., Fukuda, Y., 2003. Intravitreal injections of neurotrophic
factors and forskolin enhance survival and axonal regeneration of axotomized beta
ganglion cells in cat retina. Neuroscience 116, 733–742.
Williams, K.A., Brereton, H.M., Farrall, A., Standﬁeld, S.D., Taylor, S.D., Kirk, L.A., Coster, D.J.,
2005. Topically applied antibody fragments penetrate into the back of the rabbit eye.
Eye (Lond.) 19, 910–913.
Wu, J.T., Kral, J.G., 2005. The NF-kappaB/IkappaB signaling system: a molecular target in
breast cancer therapy. J. Surg. Res. 123, 158–169.
Yasukawa, T., Kimura, H., Tabata, Y., Ogura, Y., 2001. Biodegradable scleral plugs for
vitreoretinal drug delivery. Adv. Drug Deliv. Rev. 52, 25–36.
Yip, H.K., So, K.F., 2000. Axonal regeneration of retinal ganglion cells: effect of trophic
factors. Prog. Retin. Eye Res. 19, 559–575.
Yoon, S., Seger, R., 2006. The extracellular signal-regulated kinase: multiple substrates
regulate diverse cellular functions. Growth Factors 24, 21–44.
Zhang, S.X., Wang, J.J., Gao, G., Shao, C., Mott, R., Ma, J.X., 2006. Pigment epithelium-
derived factor (PEDF) is an endogenous antiinﬂammatory factor. FASEB J. 20,
323–325.
Zhu, X.F., Zou, H.D., 2012. PEDF in diabetic retinopathy: a protective effect of oxidative
stress. J. Biomed. Biotechnol. 2012, 580687.
